ORGANOMET
Novel organometallic anticancer compounds
| Coordinatore | THE UNIVERSITY OF WARWICK
Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie. |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 156˙795 € |
| EC contributo | 149˙559 € |
| Programma | FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | ERC-2012-PoC |
| Funding Scheme | CSA-SA(POC) |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-01-01 - 2014-04-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
THE UNIVERSITY OF WARWICK
Organization address
address: Kirby Corner Road - University House - contact info |
UK (COVENTRY) | hostInstitution | 149˙559.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Currently the most widely used drugs for the treatment of cancer are platinum compounds, used in nearly 50% of all chemotherapeutic regimens. However the platinums can suffer from problems of resistance, a limited spectrum of activity, and side-effects. Hence new agents with new mechanisms of action are urgently needed. We have discovered novel organometallic osmium and iridium compounds with more potent anticancer activity and unique mechanisms of action. Initial work on an osmium compound has demonstrated promising activity against colorectal cancer without toxic side-effects, providing an opportunity to satisfy unmet clinical needs. The ERC PoC funding will allow the discovery phase to be advanced, to turn hits into leads by establishing and validating target sites, and elucidating mechanisms of action. The techniques employed to achieve this PoC will combine high throughput proteomcs/genomics approaches with image analysis of cancer cell morphology in a mathematical analysis to determine the mechanism of action. Data from cancer models will validate the efficacy of the most active compounds. This portfolio of data, together with desk research on potential patient populations, will provide a strong basis for attracting a partner in the next stage of preclinical development.'